Pediatric acute lymphoblastic leukemia: multicenter study of the treatment by the protocol ALL IC-BFM 2002

Background . Recovery of children with acute lymphoblastic leukemia (ALL) was one the most significant achievements clinical oncohematology XX century. Success in treatment ALL became possible due to comprehensive (clinical, morphoimmunological, cytogenetic) diagnostics and development differentiated, risk-adapted protocols. The German group BFM (Berlin–Frankfurt–Munster) a pioneer creating effective programs for ALL. Its new principles approaches allow vast majority patients be cured. aim study – presentation results based on IC-BFM 2002 protocol as part multicenter long standing study. Materials methods There were 592 newly diagnosed average age 10.5 years (from 4 months 21 years). Treatment carried out according 11 clinics from 01.11.2003 16.05.2022. overall (OS), relapse-free (RFS) event-free (EFS) survivals estimated 01.07.2022. Results Complete hematological remission achieved by 33 day therapy 582 (98.3 %) cases. 10-year OS 90.4 ± 1.5 %, RFS 83.9 1.9 % EFS 82.4 %. analysis survival prognostic risk groups showed that standard 92.8 1.7 86 2.2 84.3 Among intermediate OS, 94.6 2.6 82.2 5 81.7 respectively. prognosis high-risk turned least favorable: 69.5 8.7 62 9.4 60.3 9.3 Conclusion Based high efficiency possibility achieving This reproducible both federal regional rates long-term survival. fact allows including it recommendations Ministry Health Russia.